Skip to main content
. Author manuscript; available in PMC: 2016 Jan 31.
Published in final edited form as: Cancer Res. 2014 Dec 10;75(3):519–531. doi: 10.1158/0008-5472.CAN-14-2331

Figure 3. miR-155 is required for MDSC accumulation in the tumor microenvironment.

Figure 3

(A) Percent tumor-infiltrating Gr1+CD11b+ MDSCs were determined by flow cytometry from LLC1-OVA tumor-bearing mice. (B) The absolute number of tumor-infiltrating MDSCs (n=3). (C) Percent MDSC in spleen (n=9) and peripheral blood (n=5) from LLC1-OVA tumor-bearing mice were summarized. (D) Percent CD11b+Ly6G+Ly6Clow (granulocytic) and CD11b+Ly6G−Ly6Chigh (monocytic) MDSCs were indicated within plots and summarized (n=9). Flow cytometry anlaysis of expression of ki-67 (E) and annexin-V (F) on both granulocytic and monocytic tumor-infiltrating MDSCs (n=6). (G) Bone marrow cells were cultured with GM-CSF and IL-4 for 5 d in complete culture medium or in the tumor cell conditioned medium (TCM). The cell phenotypes were examined by flow cytometry. Data are given as means ± SEM. *, p< 0.05; **, p<0.01. Data are representative of 2 independent experiments.